Cannara Biotech Inc. has announced its fiscal third quarter 2023 financial and operating results for the three- and nine-month periods ending May 31, 2023. The net revenues were $15.9 million and $39 .3 million, a 57% and 63% increase compared to the same periods of prior year. The company delivered its ninth consecutive quarter of positive Adjusted EBITDA of $3.9 million, a 129% increase compared to Q3 2022. Cannara also reached an annual production capacity of 30,500 kg of premium-grade cannabis per year, increasing production capacity by 50% since August 31, 2022.

Cannara Biotech Inc., a client of our Bristol Investor Relations company, is a vertically integrated producer of premium-grade cannabis and derivative product offerings.

Read the full press release here: Cannara Biotech Inc. Reports Record Q3 2023 Financial Results with Net Revenues of $15.9 Million and Net Income of $2.9 million